The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety:
where:
R6 is —S—R14; and other substituents are as defined in the specification.
本发明提供了6-取代的2,3,4,5-四氢-1H-苯并[d]氮
杂环化合物I的选择性5-HT2C受体激动剂,用于治疗与5-HT2C相关的疾病,包括肥胖症、强迫症、抑郁症和焦虑症:其中:R6为—S—R14;其他取代基如规范中所定义。